Security key
82835W108
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)
CUSIP: 82835W108
Q4 2021 13F Holders as of 31 Dec 2021
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 30,103,833
- Total 13F value
- $200,460,000
- Share change
- -538,713
- Put/Call ratio
- 0%
- SEC-reported price per share
- $6.66
- Number of holders
- 71
- Value change
- -$13,223,479
- Number of buys
- 44
- Number of sells
- 37
- Shares outstanding
- 99,255,583
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2021
Institutions
71
Top holders
10
SPRY full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2022
Previous quarter: Q3 2021
ARS Pharmaceuticals, Inc. SEC filings
ARS Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 82835W108
Recent filing periods:
Ownership snapshot
Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2021
13F
Lead comparable stake: 8.8%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 8.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
8.8%
FMR LLC
4.3%
RA CAPITAL MANAGEMENT, L.P.
1.8%
Boxer Capital, LLC
1.7%
VANGUARD GROUP INC
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
8.8%
|
$87,234,000
8,740,887 shares
|
— | 30 Sep 2021 |
| FMR LLC |
13F
Company
|
4.3%
|
$42,800,000
4,288,549 shares
|
— | 30 Sep 2021 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
1.8%
|
$17,387,000
1,742,186 shares
|
— | 30 Sep 2021 |
| Boxer Capital, LLC |
13F
Company
|
1.7%
|
$16,720,000
1,675,377 shares
|
— | 30 Sep 2021 |
| VANGUARD GROUP INC |
13F
Company
|
1.7%
|
$16,657,000
1,669,094 shares
|
— | 30 Sep 2021 |
| WASATCH ADVISORS LP |
13F
Company
|
1.4%
|
$14,291,000
1,431,928 shares
|
— | 30 Sep 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2021
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
71
Shares
30,103,833
Rows available
71
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2021 vs Q3 2021 Across Filers
Q3 2021 holders
73
Q4 2021 holders
71
Holder diff
-2
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 value | Q4 2021 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend